Yen Yun 4
4 · LIXTE BIOTECHNOLOGY HOLDINGS, INC. · Filed Aug 3, 2022
Insider Transaction Report
Form 4
Yen Yun
Director
Transactions
- Award
Options to Purchase Common Stock
2022-06-30+100,000→ 100,000 totalExercise: $0.74From: 2022-06-30Exp: 2027-06-30→ Common (100,000 underlying)
Holdings
- 33,333
Options to Purchase Common Stock
Exercise: $1.68From: 2018-08-04Exp: 2023-08-04→ Common (33,333 underlying) - 8,333
Options to Purchase Common Stock
Exercise: $6.60From: 2019-05-22Exp: 2024-05-22→ Common (8,333 underlying) - 100,000
Options to Purchase Common Stock
Exercise: $3.03From: 2021-06-30Exp: 2026-06-30→ Common (100,000 underlying) - 52,632(indirect: By Sino-American Cancer FDD)
Warrants to Purchase Common Stock
Exercise: $5.70From: 2020-11-30Exp: 2025-11-30→ Common (52,632 underlying) - 50,000
Options to Purchase Common Stock
Exercise: $3.21From: 2021-01-06Exp: 2026-01-06→ Common (50,000 underlying)
Footnotes (1)
- [F1]Effective June 30, 2022, the reporting person was granted stock options to purchase an aggregate of 100,000 shares, vesting on the last day of each subsequent quarter until fully vested (e.g. vesting to start on September 30, 2022).